Clinical Trial Update: A Comparative Study of Botulinum Neurotoxin Type A in Treatment of Moderate to Severe Glabellar Frown Lines [Phase 1, Phase 2]

View source ↗

Summary

A completed Phase 1/2 clinical trial evaluating Botulinum Neurotoxin Type A for moderate to severe glabellar frown lines.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Glabellar Frown Lines

Drugs mentioned

• Botulinum Neurotoxin Type A

Snippet

Sponsor: ATGC Co., Ltd. | Conditions: Glabellar Frown Lines | Phase 1, Phase 2 | Status: COMPLETED